# Sonja Crandon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sonja-crandon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,542 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 14 |
| i10-index | 16 |
| OpenAlex ID | https://openalex.org/A5023280194 |
| Works | 55 |

## Researcher papers

- [Homologous and Heterologous Covid-19 Booster Vaccinations](https://scholariq.org/papers/homologous-and-heterologous-covid-19-booster-vaccinations/)
- [Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant](https://scholariq.org/papers/rapid-decline-in-vaccine-boosted-neutralizing-antibodies-against-sars-cov-2-2/)
- [Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension](https://scholariq.org/papers/cocoa-consumption-for-2-wk-enhances-insulin-mediated-vasodilatation-without/)
- [A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas](https://scholariq.org/papers/a-phase-i-study-of-pf-04929113-snx-5422-an-orally-bioavailable-heat-shock/)
- [Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report](https://scholariq.org/papers/heterologous-sars-cov-2-booster-vaccinations-preliminary-report/)
- [Oral Glucosamine for 6 Weeks at Standard Doses Does Not Cause or Worsen Insulin Resistance or Endothelial Dysfunction in Lean or Obese Subjects](https://scholariq.org/papers/oral-glucosamine-for-6-weeks-at-standard-doses-does-not-cause-or-worsen-insulin/)
- [Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial](https://scholariq.org/papers/comparison-of-bivalent-and-monovalent-sars-cov-2-variant-vaccines-the-phase-2/)
- [Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants](https://scholariq.org/papers/immunogenicity-of-nvx-cov2373-heterologous-boost-against-sars-cov-2-variants/)
- [Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant](https://scholariq.org/papers/rapid-decline-in-vaccine-boosted-neutralizing-antibodies-against-sars-cov-2/)
- [SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses](https://scholariq.org/papers/sars-cov-2-variant-vaccine-boosters-trial-preliminary-analyses/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [Heat shock proteins research](https://scholariq.org/topics/heat-shock-proteins-research/)
- [SARS-CoV-2 detection and testing](https://scholariq.org/topics/sars-cov-2-detection-and-testing/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.